At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
LCZ696 +1 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers
In Brief
A Phase 2 clinical trial evaluating LCZ696 and Valsartan for Hypertension. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Assess mechanism of action of LCZ696 related to sodium excretion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesRussia
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMay 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedMay 13, 2011
Enrollment StartMar 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.1 years ago
Interventions
LCZ696drug
200 mg and 400 mg tablets
Valsartandrug
160 mg tablets